1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Examining the Use of Tramadol Hydrochloride as an Antidepressant

Examining the Use of Tramadol Hydrochloride as an Antidepressant

  1. NeuroChi
    Tramadol (Ultram, Ultracet) is a centrally acting synthetic opioid with analgesic efficacy
    comparable to codeine. Antinociception is attributed to low but effective affinity for the
    mu-opioid receptor (), as well as reuptake inhibition of the monoamines norepinephrine
    (NE) and serotonin (5HT). Dual action antidepressants mirtazapine (Remeron), duloxetine
    (Cymbalta), and most notably venlafaxine (Effexor), which tramadol is closely related to in
    structure, also inhibit NE and 5HT reuptake. These medications are proven effective antidepressants
    and this shared monoaminergic action resulted in the research of tramadol as a
    potential treatment for depression. The present article intends to substantiate the use of
    tramadol in this manner by analyzing several decades of research which is presented as an
    illustration of neuronal theories, as well as lab work and case studies of both the supporting
    ideas and potential hazards. Finally, the article promotes the benefits of acute action in
    comparison to modern antidepressants and the documentation of low abuse rates while
    maintaining an object view of the risks, most notably, the risk for addiction from agonist
    action on mu-receptors.